# Objective

To investigate the effects of target core temperature on neurological outcome of cardiac arrest patients treated with therapeutic hypothermia.

## Methods

We conducted a multi-center retrospective study at 16 institutions to evaluate the effect of therapeutic hypothermia on out-of-hospital cardiac arrest between January 2005 and December 2008.

The study committee entrusted each hospital with the timing of cooling, cooling methods, target temperature, duration, and rewarming rate.

## MATIOUS (CONTRO)

#### **Study Population**

Patients with therapeutic hypothermia after cardiac arrest from 2005 to 2008 in each hospitals.

#### **Inclusion Criteria**

- Adult patients who remained unconscious after resuscitation from out-of-hospital cardiac arrest.
- Presented the stable hemodynamics with drug treatments or mechanical supporting system including IABP or PCPS.

#### **Exclusion Criteria**

- Patients with pregnancy, acute aortic dissection, pulmonary thromboembolism, drug poisoning, and

## Methods (cont'd)

## **Analysis**

- Patients were divided into the L group (32~34°C) and the M group (34~35°C) according to target core temperature.
- Neurological outcome was compared at hospital discharge. A favorable outcome was defined as a Cerebral Performance Category (CPC) of 1-2.

## Results

- 1. A total of 281 patients were enrolled. The median interval from collapse to return of spontaneous circulation was 18 (12-29) minutes.
- 2. Between the L group (n=35) and the M group (n=246), the rates of survivors (74% vs. 79%) and favorable outcomes (51% vs. 57%) were not statistically different.
- 3. As compared with the M group, the L group had significantly higher rates of inadequately controlled core temperature (60% vs. 35%, p=0.005), and side effects of hypothermia (50% vs. 26%, p=0.0079).

## Table 1. Baseline Characteristics

	•
Number of patients	281
Age (years)	60 (51-68)
Male (%)	235 (84%)
Witnessed cardiac arrest (%)	247 (88%)
Performed bystander CPR (%)	145 (52%)
Time from collapse to ROSC (min)	18 (12-29)
Initial arrest rhythm: VF/VT (%)	226 (80%)
i e e e e e e e e e e e e e e e e e e e	

## Table 2. Method of Hypothermia

Cooling methods	
- Surface cooling (%)	159 (57%)
- Extracorporeal circulation (%)	102 (36%)
- Intravascular catheter (%)	8 (3%)
- Infusion of ice-cold fluid (%)	135 (48%)
Duration of cooling (hours)	27 (24-48)
Target core temperature (°C)	
- 32 ~ 33.9°C	35 (12%)
- 34 ~ 35°C	246 (88%)

## **Table 3. Comparison of Outcome**

	L group	M group	p Value
Number of patients	35	246	
Age (years)	52 (45-61)	61 (52-69)	0.0014
Target temperature (°C)	33 (33-33)	34 (34-34)	<0.0001
Duration of cooling (hrs)	49 (26-51)	26 (24-46)	0.0009
Surface cooling (%)	25 (71%)	134 (54%)	0.0688
Survival (%)	26 (74%)	195 (79%)	0.5110
Favorable outcome (%)	18 (51%)	139 (57%)	0.5897

## Table 4. Side Effects of Hypothermia

L group	M group	p Value
21 (60%)	82 (35%)	0.0050
14 (40%)	53 (22%)	0.0326
17 (50%)	64 (26%)	0.0079
6 (17%)	14 (6%)	0.0256
6 (17%)	43 (17%)	0.9608
7 (20%)	26 (11%)	0.1541
	21 (60%) 14 (40%) 17 (50%) 6 (17%) 6 (17%)	21 (60%) 82 (35%) 14 (40%) 53 (22%) 17 (50%) 64 (26%) 6 (17%) 14 (6%) 6 (17%) 43 (17%)

# Table 4 (cont'd) Side Effects of Hypothermia

#### **Definition**

1) Inadequately controlled core temperature:

Core temperature exceeds target temperature ± 0.5 °C

2) Over-cooling:

Core temperature decreases more than 0.5 °C from target temperature

# Conclusions

- 1. Target core temperature did not affect neurological outcome of cardiac arrest patients.
- 2. The lower target core temperature might cause increase of side effects.
- 3. To control core temperature adequately, further studies of cooling methods and managements are needed.

# Institutions Participated in the J-PULSE-Hypo Investigators

- Hiroshima Shimin Hospital
- · Osaka Police Hospital
- Sumitomo Hospital
- Osaka City Medical Center
- Saga University Hospital
- Nihon University Surugadai Hospital
- Kitazato University
- Yamaguchi University Hospital

- Kokura Memorial Hospital
- Sapporo City University Hospital
- Kobe City Medical Center General Hospital
- · Kagawa University Hospital
- Yokohama City Hospital
- National Cardiovascular Center
- Osaka Saiseikai Senri Hospital
- Osaka Mishima Emergency Critical Care Center

### For information regarding this presentation:

Shunji Kasaoka, MD

AMEC3, Yamaguchi University Hospital

1-1-1 Minami-Kogushi, Ube 755-8505, Japan

E-mail: skasa@yamaguchi-u.ac.jp

## Impact of Duration of Cooling in Mild Therapeutic Hypothermia on Comatose Survivors of Out-of-Hospital Cardiac Arrest: J-PULSE-Hypo Registry

Eisuke Kagawa, Masaharu Ishihara, Tatsuya Maruhashi, Naohiro Yonemoto, Hiroyuki Yokoyama, Ken Nagao, Hiroshi Nonogi, and J-PULSE-Hypo investigators

#### **Disclosure**

Eisuke Kagawa, None; Masaharu Ishihara, None; Tatsuya Maruhashi, None; Naohiro Yonemoto, None; Hiroyuki Yokoyama, None; Ken Nagao, None; Hiroshi Nonogi, a grant from the Ministry of Health, Labor and Welfare in Japan, significant, research grant.

## **Background**

Mild therapeutic hypothermia (MTH) has a neuroprotective effect and results in improved survival and neurological outcome in comatose survivors of out-of-hospital cardiac arrest.

However, the optimal duration of cooling in MTH is still unclear.

## **Purpose**


We assessed whether longer duration of cooling could provides a better neurological outcome in comatose survivors of out-of-hospital cardiac arrest treated with MTH.

#### Method 1

We conducted a multicenter retrospective study at 12 institutions to evaluate the efficacy of MTH in comatose survivors of out-of-hospital cardiac arrest treated with MTH between 2005 and 2009 in Japan (J-PULSE-Hypo). Selection of duration and procedure of cooling was determined individually by each institution. A cohort of 281 patients was registered during this study period and duration of cooling was recorded for a total of 251 enrolled patients. Patients were divided according duration groups into cooling, namely, duration of cooling less than 36 hours in Group-A and more than or equal to 36 hours in Group-B.

8 Clinical Questions from J-PULSE-Hypo in 2009

Patients characteristic
Initial Patients Evaluation (blood exam.) (Kashiwase, Nov 15 Ress:p202)
Impact of AMI/ACS (Shirai, Nov 14 Ress: p94)



#### Method 2

We assessed 30-day survival, favourable neurological outcome and complications.

A favourable neurological outcome was defined as a cerebral Pittsburgh performance category of 1 or 2 at day 30.

Complications were defined as blood transfusion, disseminated intravascular coagulation (DIC), lethal arrhythmia, infection and others.


## **Statistical Analysis 1**

continuous **Estimates** for variables are presented medians (with interquartile as ranges) and categorical variables as frequency counts and percentages. Differences in baseline characteristics were compared using the Mann-Whitney U-test for continuous variables and the chi-square or Fisher's exact test for categorical variables, as appropriate.

## Statistical Analysis 2

We used logistic regression to examine the association between duration of cooling for more than 36 hours and a favourable neurological outcome in (1) an unadjusted model, (2) a model adjusted for age and gender, and (3) a model adjusted for age, gender, witnessed cardiac arrest, by-stander CPR, initial rhythm and time interval from collapse to return of spontaneous circulation (ROSC). All tests were two-sided, and a P value of less than 0.05 was considered statistically significant.


### Distribution of Duration of Cooling




#### **Baseline Characteristics of Study Patients**

	Group-A (N = 150)	Group-B (N = 101)	P value
Age	61 (51 - 69)	58 (50 - 66)	0.16
Men	127 (85%)	84 (83%)	0.75
Witnessed Cardiac Arrest	136 (91)	84 (83%)	0.08
By-Stander CPR	76 (51%)	51 (51%)	0.98
Initial Rhythm	, ,		0.89
VF / Pulseless VT	107 (71%)	71 (71%)	
PEA	15 (10%)	7 (7%)	•
Asystole	10 (7%)	7 (7%)	
Collapse to ROSC (min)	18(11-30)	22(13-37)	0.04
<b>Total Epinephrine Dose (mg)</b>	2(2-3)	2(2-4)	0.44
Emergency Coronary Angiography	` ,	48 (48%)	0.28
Reperfusion Therapy	36 (24%)	28 (28%)	0.51





#### Favourable Neurological Outcome at 30-Day



#### **Complications**

	Group-A (N = 150)	<b>Group-B</b> (N = 101)	P Value
Any Complications	29 (19%)	41 (41%)	< 0.001
<b>Blood Transfusion</b>	15 (10%)	16 (16%)	0.17
DIC	4 (3%)	4 (4%)	0.72
Lethal Arrhythmia	7 (5%)	10 (10%)	0.11
Infection	14 (9%)	27 (27%)	< 0.001
Others	5 (3%)	5 (5%)	0.53

#### Odds Ratio of Duration of Cooling for Favourable Neurological Outcome

	Odds Ratio	95% CI	P Value
Unadjusted Model	0.83	0.50 - 1.38	0.47
Adjusted with Age, Gender	0.76	0.45 - 1.29	0.32
Adjusted with Covariates*	0.85	0.48 – 1.51	0.57

<sup>\*</sup> Adjusted with age, gender, witnessed cardiac arrest, by-stander CPR, initial rhythm, time interval from collapse to ROSC


## **Subgroup Analysis**

Because baseline severity of patients (time interval from collapse to ROSC) was different between the 2 groups, we provide additional analysis with prolonged resuscitation (time interval from collapse to ROSC of more than 30 min).

**Baseline Characteristics of Patients with Prolonged Resuscitation** 

	Group-A (N = 39)	Group-B (N = 29)	P Value
Age	58 (53 - 67)	56 (50 - 63)	0.21
Men	37 (95%)	23 (79%)	0.06
Witnessed Cardiac Arrest	33 (85%)	18 (62%)	0.03
By-Stander CPR	22 (56%)	13 (45%)	0.34
Initial Rhythm			0.90
VF / Pulseless VT	27 (69%)	21 (75%)	
PEA	5 (13%)	2 (7%)	
Asystole	4 (10%)	3 (11%)	
Collapse to ROSC (min)	51 (36 – 68)	47(40-75)	0.47
Total Epinephrine Dose (mg)	3(2-4.5)	2(2-5)	0.84
Emergency Coronary Angiography	22 (56%)	13 (45%)	0.34
Reperfusion Therapy	16 (41%)	9 (31%)	0.40


#### 30-Day Survival of Patient with Prolonged Resuscitation



**Prolonged Resuscitation** 

**Prolonged Resuscitation** 

## Favourable Neurological Outcome for Patient with



# Complications in Patients with Prolonged Resuscitation

	Group-A $(N = 39)$	Group-B $(N = 29)$	P value
Any Complications	14 (36%)	15 (56%)	0.11
<b>Blood Transfusion</b>	8 (21%)	7 (24%)	0.72
DIC	2 (5%)	2 (7%)	>0.99
Lethal Arrhythmia	4(10%)	4 (14%)	0.72
Infection	4 (10%)	9 (31%)	0.03
Others	2 (5%)	1 (3%)	>0.99

### Summary

- ✓ In the entire cohort, there was no significant difference in the 30-day survival rate (83% vs. 84%, P = 0.74) and favourable neurological outcome (60% vs. 55%, P = 0.47) between the 2 groups. Complications occurred more frequently in group-B than in group-A (19% vs. 41%, P < 0.01).
- ✓ Time interval from collapse to ROSC was significantly longer in group-A than in group-B(median 18 min vs. 22 min, P = 0.04).
- ✓ When adjusting for covariates, no significant association was observed between cooling duration of more than 36 hours and favourable neurological outcome.
- ✓ In patients with prolonged resuscitation, similar findings were observed.

### **Study Limitations**

This study was a non-randomized study and has limitations common to all retrospective investigations. The duration of cooling was not analyzed according to an intention-to-treat policy in this study. As more critically ill patients could have cooled longer, we attempted to adjust for possible selection bias by multivariate and subgroup analysis.

#### **Conclusions**

Duration of Cooling of more than 36 hours may not provide better neurological outcome, but increase complications in comatose survivors of out-of-hospital cardiac arrest treated with MTH.

Impacts of Percutaneous Assisted Devices and Mild Hypothermia Therapy for Out-of-Hospital Cardiac Arrest in Patients from Multicenter Hypothermia Registry in Japan: J-Pulse-Hypo registry

Nobuaki Kokubu Hiroyuki Yokoyama, Yoritaka Otsuka, Nobihito Yagi, Futoshi Yamanaka, Naohiro Yonemoto\*, Ken Nagao∮, Hiroshi Nonogi

> National Cardiovascular Center, Suita, Japan \*Kyoto University, Kyoto, Japan § Nihon University, Tokyo, Japan

> > AHA Ress 2009

National Cardiovascular Center

#### **Presenter Disclosure Information**

Nobuaki Kokubu, MD
Impacts of Percutaneous Assisted Devices and Mild
Hypothermia Therapy for Out-of-Hospital Cardiac Arrest in
Patients from Multicenter Hypothermia Registry in Japan:
J-Pulse-Hypo registry

FINANCIAL DISCLOSURE: None

UNLABELED/UNAPPROVED USES DISCLOSURE: None

AHA Ress 2009